

1

Supplementary Information

2

A simple and rapid method to assay SARS-CoV-2 RNA based on primer exchange reaction

3

4 *Dayong Li,^a Chengjie Duan,^a Wenting Cheng,^a Youjing gong,^a Yanheng Yao,^a Xiaoping*
5 *Wang,^{*c} Zhongyun Wang^{*d} and Yang Xiang^{*ab}*

6

7 ^aState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences,
8 Nanjing University, Nanjing 210023, P. R. China

9 ^bState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing
10 100191, P. R. China

11 ^cDepartment of Neurology, Tongren Hospital, Shanghai Jiao Tong University School
12 of Medicine, Shanghai, 200336, P. R. China.

13 ^dDepartment of Anesthesiology, The First Affiliated Hospital of Nanjing Medical
14 University, Nanjing 210029, P. R. China

15

16 *Corresponding authors: xiangy@nju.edu.cn (Y. Xiang),

17 wangxp@ustc.edu (X. Wang), zywang1970@126.com (Z. Wang)

18

19

20 Reagents and materials

21 All the DNA oligonucleotides used in this work were obtained from Sangon
22 Biotech. Co. Ltd. (Shanghai, China). The RNA sequence was synthesized by Genscript.
23 Bio Tech (Nanjing China) (Table S1). The target RNA used in this study is the
24 artificially synthesized conserved regions (ORF1ab fragment) of SARS-CoV-2 RNA

25 according to GenBank, SARS-CoV-2 NC_045512. Large Fragment Bst DNA
26 polymerase, 10x Bst Reaction Buffer (200mM Tris-HCl, 100mM KCl, 100mM
27 $(\text{NH}_4)_2\text{SO}_4$, 20mM MgSO_4 , 1% Triton X-100) and 100mM MgSO_4 were bought from
28 Beyotime Biotech. (Shanghai China). dATP (100 mM), dTTP (100 mM), dCTP (100
29 mM) were bought from Sangon Biotech. Co. Ltd. (Shanghai, China). RNase free water
30 and RNase inhibitor were obtained from Takara Bio. (Dalian China). EnGen® Lba
31 Cas12a (Cpf1) and 10×NEbuffer 2.1 were purchased from New England Biolabs
32 (Beijing China). Ultra-pure water used in all experiments were purified by a Millipore
33 purification system. Human serum was provided by the First Affiliated Hospital of
34 Nanjing Medical University. Our research has been approved by the ethics committee
35 of Nanjing Medical University and Nanjing University.

36 **Native polyacrylamide gel electrophoresis**

37 The products of the PER cascade were verified by 12% non-denaturing gel
38 electrophoresis. Specifically, we mixed 100nM target RNA with 100nM HP and
39 500nM primers, and then added Bst DNA polymerase (0.4U/ μL) and 200 μM dNTPs
40 (A, T, C) to initiate the PER cascade. After two hours of reaction at 37°C, 10 μL of the
41 reaction solution was incubated with nucleic acid dye for 1 minute. Subsequently, the
42 reaction solution was injected into the 12% PAGE. After running for 1 hour at 100V in
43 1 × TBE buffer, the gel is finally scanned by the gel imaging system.

44 **Detection protocol for SARS-COV-2 RNA**

45 Firstly, different concentrations of target RNA are added to the reaction solution
46 with a total volume of 20 μL , which contains 2nM HP and 10nM primers, 0.2U/ μL Bst
47 DNA polymerase, 4 μL 1mM dNTP (A, T, C), 2 μL 10×Bst reaction Buffer and
48 3 μL 100mM MgSO_4 . Then, the mixed solution was reacted at 37°C for 30 min. Next,
49 2 μL 1 μM cas12a, 2 μL 1 μM CrRNA, 2 μL 10 μM fluorescence reporter, 5 μL
50 10×NEbuffer 2.1, and 19 μL RNase free water were added into the solution to reach a
51 total volume of 50 μL . After reacting for 10 minutes at 37°C, the solution was finally

52 transferred to a black 96-well plate to measure its fluorescence value through Infinite
 53 200Pro (Excitation 485nm, Emission 525 nm). When detecting target RNA in complex
 54 biological samples of serum and saliva, except for the need to add RNase inhibitor to
 55 prevent RNA degradation, the other steps are the same as above.


56

57 Table S1. DNA and RNA sequences used in this work

Name	Sequence (5' to 3')
HP (15bp)	ACTAAATTCAGGGCCTTTTGGCCCTGAATTTAGTAATA AGAGATCAACTACTGAAGCATGGGTTCGCGGAGTTGA TCTCTTATT-Inverted dT
HP (17bp)	ACTAAATTCAGGGCCTTTTGGCCCTGAATTTAGTAATA AGAGATCAACTCCACTGAAGCATGGGTTCGCGGAGTT GATCTCTTATT-Inverted dT
HP (19bp)	ACTAAATTCAGGGCCTTTTGGCCCTGAATTTAGTAATA AGAGATCAACTCCGCACTGAAGCATGGGTTCGCGGAG TTGATCTCTTATT-Inverted dT
HP (21bp)	ACTAAATTCAGGGCCTTTTGGCCCTGAATTTAGTAATA AGAGATCAACTCCGCGACTGAAGCATGGGTTCGCGGA GTTGATCTCTTATT-Inverted dT
primer	ATCTC TTAT
Target virus RNA	UUUUUGAUCAACUCCGCGAACCCAUGCUUCAGUUUU UU
Single-base mismatched RNA (1M)	UUUUUGAUCAAGUCCGCGAACCCAUGCUUCAGUUUU UU
Two-base mismatched RNA (2M)	UUUUUGAUCAAGUCCGCGAACCCAUGCUACAGUUUU UU
Three-base mismatched RNA (3M)	UUUUUGAUCAAGUCCGCGAACCCAUGCUACAGUUUU UU
random DNA	TCAACATCAGTTGGCACCCATGTGATATCCTTTTT
CrRNA	UAAUUUCUACUAAGUGUAGAUUGAAUUUAGUAAUA AGAGAU
excitation DNA	ATCTCTTATTACTAAATTCA
Fluorescence reporter (FQ)	FAM-TTATT-BHQ1

58 Red sequences represent conserved regions of the SARS-CoV-2 RNA.

59




60

61 Fig. S1. The verification of trans-cleavage activity of cas12a protein (cpfl). Excitation
 62 DNA is 5nM, cas12a is 40nM, CrRNA is 40nM and fluorescence reporter (FQ) is
 63 400nM. Reaction time is 15min.


64

65



66

67 Fig. S2. Influence of the concentration ratio of HP to primer (A) and the PER
 68 temperature (B) on the detection performance of the PER-based method. Target RNA
 69 is 5nM and HP is 2nM.



71 Fig. S3. Influence of the concentration of Bst DNA polymerase (A), Mg²⁺ concentration
 72 (B) and the PER reaction time (C) on the final detection performance of the biosensor.
 73 Target RNA is 5nM, HP is 2nM and primer is 10nM.

74

75

76 Table S2. Comparison with some reported detection strategies for SARS-CoV-2 RNA.

Signal output mode	LOD	Detection time	Tested mutated SARS-CoV-2	References
Fluorescence	500 pM	60min	No	[1]
Colorimetry	140 pM	90min	No	[2]
Colorimetry	30.3 fM	141min	Yes	[3]
Electrochemistry	26 fM	185min	Yes	[4]
Fluorescence	1.3 pM	40min	Yes	This work

78 Table S3. Results for the detection of target RNA in 1xBst reaction buffer, 10% human
79 serum and 10% saliva samples.

Sample number	Samples	Added(nM)	Found(nM)	Recovery (%)	RSD (%) n=3
1	Buffer	0.2	0.214	107	5.3
2	Buffer	2	1.993	99.6	2.1
3	10% Serum	0.2	0.214	107	3.4
4	10% Serum	2	2.04	102	4.1
5	10% Saliva	0.2	0.207	103.5	3.9
6	10% Saliva	2	1.992	99.6	3.0

80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

95 **References**

- 96 1. M. Q. Liu, H. R. Li, Y. W. Jia, P. I. Mak and R. P. Martins, *Micromachines*, 2021, **12**, 11.
97 2. J. Moon, H. J. Kwon, D. Yong, I. C. Lee, H. Kim, H. Kang, E. K. Lim, K. S. Lee, J. Jung, H. G.
98 Park and T. Kang, *ACS Sens.*, 2020, **5**, 4017-4026.
99 3. R. Liu, Y. S. Hu, Y. He, T. Lan and J. J. Zhang, *Chem. Sci.*, 2021, **12**, 9022-9030.
100 4. Y. Peng, Y. H. Pan, Z. W. Sun, J. L. Li, Y. X. Yi, J. Yang and G. X. Li, *Biosens. Bioelectron.*,
101 2021, **186**, 6.
102